Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.




We have used our CRM pump-priming award to develop a novel line of transgenic reporter mice where macrophage-specific human CD68 gene regulatory elements drive expression of a Tamoxifen inducible version of the Cre recombinase protein. We believe that this new transgenic mouse line will offer significant advantages over other Cre driver lines to study the role of macrophages in development and in post myocardial infarction repair.